Evra transdermal patch - Summary of Product Characteristics (SPC)EVRA 2. Each 2. 0 cm. 2 transdermal patch contains 6 mg norelgestromin (NGMN) and 6. EE). Each transdermal patch releases an average of 2. NGMN and 3. 3. 9 micrograms of EE per 2. Medicinal product exposure is more appropriately characterised by the pharmacokinetic profile (see section 5. For the full list of excipients, see section 6. Transdermal patch.
Thin, matrix- type transdermal patch consisting of three layers. The outside of the backing layer is beige and heat- stamped “EVRA”. Female contraception. EVRA is intended for women of fertile age. The safety and efficacy has been established in women aged 1. The decision to prescribe EVRA should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with EVRA compares with other CHCs (see sections 4. Posology. To achieve maximum contraceptive effectiveness, patients must be advised to use EVRA exactly as directed.
For initiation instructions see 'How to start EVRA' below. Only one transdermal patch is to be worn at a time. Each used transdermal patch is removed and immediately replaced with a new one on the same day of the week (Change Day) on Day 8 and Day 1. Transdermal patch changes may occur at any time on the scheduled Change Day.
COLLECTION OF THE PRIVATE BIRD-SKIN AND SKELETON COLLECTION. JOHANNES ERRITZOE (Open for scientific research) Copyright 1993 Johannes Erritzoe, latest revised 2016. Document overview: Introduction Short history of the. Fungal infections of the hair, skin or nails - including symptoms, treatment and prevention These infections are commonly called 'ringworm', but are not caused by worms. They are superficial infections of the skin, hair. Vintage fashion dolls such as Pippa, Sindy and Tressy and other vintage dolls.
The fourth week is transdermal patch- free starting on Day 2. A new contraceptive cycle begins on the next day following transdermal patch- free week; the next EVRA transdermal patch should be applied even if there has been no withdrawal bleeding or if withdrawal bleeding has not yet stopped.
Seabright Marine, inflatable boat, inflatable boats, seabright, seabright Inflatable Boats Canada, Rigid Hull, Bateau Pneumatique, RIB, Zodiac Inflatable Boat, zodiac, inflatable zodiac, halifax zodiac, tenders, inflatable. Cat eye problems should be extremely important to the cat owner. Cat's eyes have special characteristics that set them apart from other animals. Here we help categorize the most common ones. Rose water is used in a variety of ways in skin care treatments. The best part of using rose water for skin is that it is suitable for every skin type. Whether you have an oily skin or a dry one, sensitive skin or. Say goodbye to DARK skin and unleash the Beauty within. Achieve that radiantly glowing, flawless and light skin celebrities have. The answer to your skin.
Under no circumstances should there be more than a 7- day transdermal patch- free interval between dosing cycles. If there are more than 7 transdermal patch- free days, the user may not be protected against pregnancy. A non- hormonal contraceptive must then be used concurrently for 7 days. The risk of ovulation increases with each day beyond the recommended contraceptive- free period. If intercourse has occurred during such an extended transdermal patch- free interval, the possibility of pregnancy should be considered. Special populations. Body weight equal or greater than 9.
Contraceptive efficacy may be decreased in women weighing equal or greater than 9. Renal impairment. EVRA has not been studied in women with renal impairment. No dose adjustment is necessary but as there is a suggestion in the literature that the unbound fraction of ethinyl estradiol is higher, EVRA should be used with supervision in this population. Hepatic impairment.
EVRA has not been studied in women with hepatic impairment. EVRA is contraindicated in women with hepatic impairment (see section 4.
Post- menopausal women. EVRA is not indicated for post- menopausal women and is not intended for use as hormonal replacement therapy. Paediatric population. Safety and efficacy have not been established in adolescents under 1. There is no relevant use of EVRA in children and pre- menarchal adolescents. Method of administration.
EVRA should be applied to clean, dry, hairless, intact healthy skin on the buttock, abdomen, upper outer arm or upper torso, in a place where it will not be rubbed by tight clothing. EVRA should not be placed on the breasts or on skin that is red, irritated or cut. Each consecutive transdermal patch should be applied to a different place on the skin to help avoid potential irritation, although they may be kept within the same anatomic site. The transdermal patch should be pressed down firmly until the edges stick well. To prevent interference with the adhesive properties of the transdermal patch, no make- up, creams, lotions, powders or other topical products should be applied to the skin area where the transdermal patch is placed or where it will be applied shortly. It is recommended that users visually check their transdermal patch daily to ensure continued proper adhesion.
The EVRA transdermal patch should not be cut, damaged or altered in any way as this may compromise contraceptive effectiveness. Used transdermal patches should be discarded carefully in accordance with the instructions given in section 6. How to start EVRAWhen there has been no hormonal contraceptive use in the preceding cycle.
Contraception with EVRA begins on the first day of menses. A single transdermal patch is applied and worn for one full week (7 days). The day the first transdermal patch is applied (Day 1/Start Day) determines the subsequent Change Days. The transdermal patch Change Day will be on this day every week (cycle Days 8, 1. Day 1 of the next cycle). The fourth week is transdermal patch- free starting on Day 2. If Cycle 1 therapy starts after first day of the menstrual cycle, a non- hormonal contraceptive should be used concurrently for the first 7 consecutive days of the first treatment cycle only.
When switching from an oral combined contraceptive. Treatment with EVRA should begin on the first day of withdrawal bleeding. If there is no withdrawal bleeding within 5 days of the last active (hormone containing) tablet, pregnancy must be ruled out prior to the start of treatment with EVRA. If therapy starts after the first day of withdrawal bleeding, a non- hormonal contraceptive must be used concurrently for 7 days. If more than 7 days elapse after taking the last active oral contraceptive tablet, the woman may have ovulated and should, therefore, be advised to consult a physician before initiating treatment with EVRA. If intercourse has occurred during such an extended pill- free interval, the possibility of pregnancy should be considered.
When changing from a progestogen- only- method. The woman may switch any day from the progestogen- only pill (from an implant on the day of its removal, from an injectable when the next injection would be due), but a back- up barrier method of birth control must be used during the first 7 days. Following abortion or miscarriage. After an abortion or miscarriage that occurs before 2. EVRA may be started immediately. An additional method of contraception is not needed if EVRA is started immediately. Be advised that ovulation may occur within 1.
After an abortion or miscarriage that occurs at or after 2. EVRA may be started either on Day 2. The incidence of ovulation on Day 2. Following delivery. Users who choose not to breast- feed should start contraceptive therapy with EVRA no sooner than 4 weeks after child- birth.
When starting later, the woman should be advised to additionally use a barrier method for the first 7 days. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of EVRA or the woman has to wait for her first menstrual period. For breast- feeding women, see section 4. What to do if the transdermal patch comes off or partly detaches. If the EVRA transdermal patch partly or completely detaches and remains detached, insufficient medicinal product delivery occurs. If EVRA remains even partly detached: - for less than one day (up to 2. EVRA transdermal patch immediately.
No additional contraceptive is needed. The next EVRA transdermal patch should be applied on the usual “Change Day”.- for more than one day (2. The user should stop the current contraceptive cycle and start a new cycle immediately by applying a new EVRA transdermal patch.
There is now a new “Day 1” and a new “Change Day”. A non- hormonal contraceptive must be used concurrently for the first 7 days of the new cycle only. A transdermal patch should not be re- applied if it is no longer sticky; a new transdermal patch should be applied immediately. Supplemental adhesives or bandages should not be used to hold the EVRA transdermal patch in place.
If subsequent EVRA transdermal patch change days are delayed. At the start of any transdermal patch cycle (Week One/Day 1)The user may not be protected from pregnancy. The user should apply the first transdermal patch of the new cycle as soon as remembered. There is now a new transdermal patch “Change Day” and a new “Day 1”. A non- hormonal contraceptive must be used concurrently for the first 7 days of the new cycle. If intercourse has occurred during such an extended transdermal patch- free interval, the possibility of pregnancy should be considered.
In the middle of the cycle (Week Two/Day 8 or Week Three/Day 1. The user should apply a new EVRA transdermal patch immediately. The next EVRA transdermal patch should be applied on the usual “Change Day”. If during the 7 days preceding the first skipped day of transdermal patch application, the transdermal patch was worn correctly, no additional contraceptive use is required.- for more than two days (4. The user may not be protected from pregnancy. The user should stop the current contraceptive cycle and start a new four- week cycle immediately by putting on a new EVRA transdermal patch.
There is now a new “Day 1” and a new “Change Day”. A non- hormonal contraceptive must be used concurrently for the first 7 consecutive days of the new cycle.
At the end of the cycle (Week Four/Day 2. If the EVRA transdermal patch is not removed at the beginning of Week 4 (Day 2.
The next cycle should begin on the usual “Change Day”, which is the day after Day 2. No additional contraceptive use is required. Change day adjustment.
In order to postpone a menstrual period for one cycle, the woman must apply another transdermal patch at the beginning of Week 4 (Day 2. Breakthrough bleeding or spotting may occur. After 6 consecutive weeks of transdermal patch wear, there should be a transdermal patch- free interval of 7 days. Following this, the regular application of EVRA is resumed.
If the user wishes to move the Change Day the current cycle should be completed, removing the third EVRA transdermal patch on the correct day. During the transdermal patch- free week a new Change Day may be selected by applying the first EVRA transdermal patch of the next cycle on the first occurrence of the desired day. In no case should there be more than 7 consecutive transdermal patch- free days.